Yahoo · Nov 19, 2026
Moderna: Can the Vaccine Business Fund Its Next Phase of Growth?
MRNA's ambitious oncology investments and expanding vaccine portfolio drive growth, but rising costs and uncertain revenues test its financial recovery.

NYSE · MRK
Healthcare · Drug Manufacturers - General
$137.78
Down-$5.04 (-3.66%)
Updated Nov 20, 2026, 1:45 AM
SID Score
7.5/10
Composite research score
Smart Money
52/100
Neutral
Price performance · MRK
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 18, 2026
MRK closed at $137.78 after 20 trading sessions, down 6.42% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 18, 2026 | $141.09 | $142.34 | $136.7897 | $137.78 | 9.7M |
| Nov 17, 2026 | $143.32 | $144.89 | $142.31 | $143.37 | 7.27M |
| Nov 16, 2026 | $147.895 | $149.23 | $144.25 | $144.46 | 8.65M |
| Nov 13, 2026 | $147.31 | $147.99 | $145.24 | $147.76 | 6.51M |
| Nov 12, 2026 | $148.61 | $149.31 | $146.86 | $146.95 | 6.11M |
| Nov 11, 2026 | $146.61 | $147.62 | $145.30 | $147.18 | 6.41M |
| Nov 10, 2026 | $148.40 | $149.19 | $145.575 | $148.05 | 5.51M |
| Nov 9, 2026 | $148.37 | $148.80 | $146.52 | $148.76 | 7.57M |
| Nov 6, 2026 | $144.34 | $147.48 | $142.80 | $146.73 | 7.63M |
| Nov 5, 2026 | $152.00 | $153.3699 | $146.545 | $146.94 | 11.55M |
| Nov 4, 2026 | $148.54 | $150.42 | $146.05 | $150.36 | 10.72M |
| Nov 3, 2026 | $147.015 | $147.62 | $143.47 | $144.67 | 8.89M |
| Nov 2, 2026 | $148.82 | $150.265 | $147.10 | $148.36 | 9.1M |
| Oct 30, 2026 | $149.55 | $151.35 | $147.40 | $149.52 | 12.35M |
| Oct 29, 2026 | $144.62 | $149.26 | $143.32 | $146.33 | 13.45M |
| Oct 28, 2026 | $140.00 | $142.40 | $139.211 | $140.93 | 8.24M |
| Oct 27, 2026 | $140.22 | $142.69 | $139.8301 | $141.82 | 9.06M |
| Oct 26, 2026 | $145.89 | $146.61 | $139.93 | $140.61 | 13.1M |
| Oct 23, 2026 | $145.02 | $145.44 | $143.41 | $145.27 | 8.38M |
| Oct 22, 2026 | $151.05 | $154.02 | $144.0701 | $147.24 | 19.03M |
The latest Smart Investors Daily articles mentioning MRK.
Company
Market Activity
Research & News
MRK research
Company profile and research snapshot.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 2, 2026 | Cantor Fitzgerald | Neutral | — |
| Nov 2, 2026 | Freedom Broker | Hold | — |
| Oct 30, 2026 | RBC Capital | Sector Perform | — |
| Oct 30, 2026 | Guggenheim | Buy | — |
| Oct 30, 2026 | JP Morgan | Overweight | — |
No generated briefing is available yet.
Yahoo · Nov 19, 2026
MRNA's ambitious oncology investments and expanding vaccine portfolio drive growth, but rising costs and uncertain revenues test its financial recovery.
Yahoo · Nov 19, 2026
Halozyme said it would immediately file a patent infringement lawsuit against Merck in Germany, seeking permanent relief
Yahoo · Nov 19, 2026
Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme), today provided an update on the German preliminary injunction hearing that overturned the decision issued in December 2025, ordering Merck to refrain from distributing and offering Keytruda SC in Germany.
Yahoo · Nov 19, 2026
Merck & Co. (NYSE:MRK) has entered into a research collaboration with Isomorphic Labs to identify and develop potential small-molecule cancer treatments using artificial intelligence, combining the pharmaceutical group’s drug discovery expertise with advanced computational modelling technology.
Interpretive context generated from the platform’s current data sources.
Merck & Co. (MRK) shares traded at $137.78, reflecting a single-session decline of 2.49% per SID market data. Over the trailing one-month period, the stock posted a marginal loss of 0.18%, while the three-month return registered a steeper decline of 5.80%. On a twelve-month basis, however, MRK delivered a gain of 29.15%, demonstrating sustained longer-term strength within the Healthcare sector. The stock currently trades below its 50-day moving average of $145.91, indicating near-term price weakness, but remains above its 200-day moving average of $128.88, which supports the broader uptrend. The 14-day relative strength index stands at 53.8, positioning the stock in neutral territory between overbought and oversold thresholds. According to Massive/Polygon data, average daily trading volume is approximately 13.42 million shares. MRK's beta of 0.299 reflects significantly lower volatility relative to the broader market, consistent with its defensive Healthcare classification.
Merck & Co. carries a market capitalization of approximately $248.8 billion, positioning it among the largest companies in the global Healthcare sector, according to SID market data. The stock trades at a price-to-earnings ratio of 12.99, which sits below the broader S&P 500 average, suggesting a relatively modest earnings multiple for a large-cap pharmaceutical name. The PEG ratio stands at 0.79, falling below the commonly referenced 1.0 threshold, which indicates the current valuation may not fully reflect projected earnings growth, per SEC filings. Merck's price-to-book ratio registers at 4.77, reflecting the premium typically associated with pharmaceutical companies that hold significant intangible assets including patents and drug pipelines. The company offers a dividend yield of 3.27%, providing meaningful income return to shareholders. This yield level positions MRK competitively among Healthcare peers and adds a defensive income component to the total return profile for investors.
Merck & Co. registers a composite smart money score of 52 out of 100 with a neutral overall signal, according to SID market data. The institutional ownership component scores a perfect 25 out of 25, reflecting maximum conviction from large fund managers and signaling broad institutional endorsement of the stock. Congressional trading activity scores 12.3 out of 25, indicating moderate engagement from lawmakers. The insider trading component scores 6.3 out of 25, with SEC Form 4 filings revealing six insider transactions over the past 90 days — five purchases against just one sale. This five-to-one buy-to-sell ratio among corporate insiders suggests internal confidence in the company's forward trajectory. Dark pool activity registers at 8.5 out of 25, indicating below-average off-exchange trading volume relative to comparable large-cap peers. The divergence between strong institutional conviction and more muted insider and dark pool signals produces the overall neutral composite reading, suggesting no dominant directional bias from sophisticated market participants at current price levels.
Merck & Co.'s most recent quarterly earnings report, filed on October 29, showed earnings per share of $2.49 against a consensus analyst estimate of $2.10, representing a positive surprise of $0.39, or approximately 18.6%, per company earnings reports. This followed a mixed sequence of prior results. The quarter reported on August 4 showed a loss of $0.13 per share, missing the $0.23 estimate by $0.36. The April 30 quarter recorded a larger loss of $1.28 per share, though this actually exceeded expectations by $0.20 as analysts had projected a loss of $1.48. Looking ahead, analyst estimates compiled for the upcoming reporting period project earnings of $0.30 per share, with results expected on July 28. The pattern of alternating beats and misses across recent quarters reflects the volatility inherent in Merck's earnings trajectory, driven by pipeline-related charges and revenue timing from key pharmaceutical franchises.
Wall Street analyst coverage of Merck & Co. reflects a divided but moderately constructive consensus, per SID consensus data. In the most recent round of post-earnings rating updates, JP Morgan reiterated its Overweight rating on November 2, while Guggenheim maintained a Buy rating, both representing the bullish contingent among covering analysts. Counterbalancing these positive views, Cantor Fitzgerald reiterated a Neutral rating, Freedom Broker maintained a Hold designation, and RBC Capital reaffirmed its Sector Perform stance, all issued between October 30 and November 2 according to Wall Street analyst reports. Notably, none of the five most recent rating actions involved a directional change — each firm held its prior position, suggesting the latest earnings results did not materially alter fundamental outlooks. The split of two bullish ratings against three neutral positions indicates that a meaningful portion of the analyst community views MRK as fairly valued near the $137.78 level, while others see additional upside potential from current prices.


The latest Smart Investors Daily articles mentioning MRK.